Rx-TO-OTC SWITCHES REPRESENT "BIGGEST" OPPORTUNITY FOR DRUG WHOLESALERS
This article was originally published in The Tan Sheet
Executive Summary
Rx-TO-OTC SWITCHES REPRESENT "BIGGEST" OPPORTUNITY FOR DRUG WHOLESALERS and manufacturers alike to boost sales and profits amidst the current health care reform climate, Schering-Plough HealthCare Products Senior VP-Trade Development Raymond Modjeski suggested at the National Wholesale Druggists' Association's annual marketing conference in Orlando, Fla. on March 8. Pointing out that "not one Rx-to-OTC switch product has failed in the marketplace; all have captured a leading marketshare within the first couple of years," Modjeski proclaimed that "in these challenging economic times, Rx-to-OTC switches just may be your biggest opportunity for incremental sales and profits."
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning